Editorial: a need for glucose monitoring on prokinetic treatment with a ghrelin agonist in diabetic gastroparesis?

Abstract

Prokinetics that accelerate delayed gastric emptying are mainstays of gastroparesis therapy. Only metoclopramide was approved by the US Food and Drug Administration for gastroparesis over 40 years ago. Because of the largely non-fatal nature of symptoms, much of the focus on gastroparesis therapy has been on safety of prokinetics. Metoclopramide prescriptions for patients with gastroparesis have decreased from 69.8% to 23.7% due to concerns about tardive dyskinesia. 1 Case-control studies documenting increased sudden cardiac deaths led to 40%-70% reductions in domperidone prescriptions. 2 Relamorelin is a promising ghrelin agonist that significantly improved symptoms in phase 2a and 2b trials in diabetic gastroparesis. Camilleri et al have highlighted the critical topic of its safety. 3 There

Editorial: a need for glucose monitoring on prokinetic treatment with a ghrelin agonist in diabetic gastroparesis? Author's reply

“…We thank Dr Hasler for the excellent discussion points that he raised in the editorial relating to our article on the safety of relamorelin in adult patients with diabetic gastroparesis 1,2 …”